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ABSTRACT
CANNABIS USE AND AFFECTIVE PROCESSING: A BRAIN STRUCTURE ANALYSIS
by
Kristin E. Maple
The University of Wisconsin—Milwaukee, 2016
Under the Supervision of Professor Krista Lisdahl
Cannabis is the most commonly used illicit drug amongst adolescents and young adults
in the United States. Previously, cannabis and its components have been associated
with differences in affective processing and neural functioning. Participants (ages 16-25)
were cannabis users and non-users excluded for psychiatric disorders, major medical
conditions, and excessive other drug use. A series of multiple regressions examined
whether past year cannabis use and cannabis x gender predicted measures of
emotional face processing (using the PennCNP affective battery) as well as volumes in
bilateral prefrontal, temporal, limbic, and cerebellar regions, as well as frontolimbic white
matter tracts. Subsequently, Pearson correlations were conducted within the cannabis
group to assess whether brain regions significantly associated with cannabis use
predicted mood and affective processing. Increased cannabis use was associated with
higher Acuity Neutral scores, smaller left rostral anterior cingulate (rACC) volumes,
larger superior temporal volumes, and reduced right uncinate fasciculus mean
diffusivity. Significant cannabis x gender interactions were observed for left rACC and
forceps minor fractional anisotropy (FA). Greater cannabis use was associated with
smaller left rACC volumes only within females, as well as greater forceps minor FA in
females and reduced FA in males. Within the cannabis-using group, smaller rACC
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volumes were correlated with lower Emotion Discrimination Correct scores. These
findings suggest that cannabis use exerts dose dependent effects on frontolimbic
circuitry, which are in turn associated with deficits in affective processing. This may be
one potential mechanism underlying high comorbidity rates between chronic cannabis
use and psychiatric disorders.
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Cannabis Use and Affective Processing: A Brain Structure Analysis
Cannabis is the most commonly used illicit drug in the United States, with 35.1% of
12th graders and 31.6% of 19-28 year-olds using in the past year (Johnston et al.,
2015a; Johnston et al., 2015b). Furthermore, the perceived risk of using cannabis has
dropped substantially amongst this population since 2005 (Johnston et al., 2015a;
Johnston et al., 2015b). This decrease in perceived risk has occurred in parallel with
many states proposing, and some passing, legislation to legalize medicinal and
recreational cannabis use. Currently, recreational use is legal in Colorado, Washington,
Oregon, Alaska, and Washington, D.C. Experts have predicted that with legalization, the
price of cannabis is likely to drop, and consumption is likely to increase (Caulkins et al.,
2012). Given that cannabis use is widespread and may increase further, research on its
potential neurocognitive effects in young people is critical.
Adolescents and emerging adults may be especially vulnerable to the negative
effects of cannabis use due to the substantial neurodevelopment occurring during this
period (Lisdahl et al., 2013; Lisdahl et al., 2014; Jacobus & Tapert, 2014). Although at
age six the brain is approximately 90% of its adult weight, neurodevelopment continues
into the late 20’s (Casey, Jones, & Hare, 2008). White matter volume and integrity
increase, enhancing neural efficiency (Giedd et al., 1999; Lebel et al., 2008; Lebel &
Beaulieu, 2011). The adolescent brain also undergoes significant synaptic pruning in
regions associated with higher-order and executive function, such as the prefrontal
cortex (PFC) (Casey et al., 2008). The PFC is one of the last areas to mature, lagging
behind subcortical limbic regions involved in affect, such as the amygdala (Casey et al.,
2008). According to Casey and colleagues’ (2008) model, when adolescents are
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presented with an emotionally-charged situation, limbic regions will override the
prefrontal executive system, leading to increased risk taking, impulsivity, and emotional
reactivity. Thus, adolescents may be more likely to engage in risky behavior such as
substance use, and are at greater risk of developing a substance use disorder
compared to those initiating use as adults (Chambers et al., 2003; Casey et al., 2008;
Bava & Tapert, 2010). Given the increased likelihood to abuse substances, including
cannabis, during a time when the brain is particularly vulnerable to their neurotoxic
effects, adolescence and emerging adulthood is the ideal period to research and target
substance use interventions (Squeglia, et al., 2009; Lisdahl et al., 2013).
The Endogenous Cannabinoid System: Neurodevelopment & Affective
Processing
The main psychoactive component of cannabis, Δ-9-tetrahydrocannabinol (THC),
exerts its effects by binding brain cannabinoid receptor-1 (CB1) in the endocannabinoid
(eCB) system (Howlett, 1995). Cannabidiol (CBD) is another cannabinoid found in
herbal cannabis, but typically in low doses. In cannabis, THC content is typically much
higher compared to CBD, with published mean THC levels at 8.8% and CBD at 0.4% in
the U.S. in 2008 (Mehmedic et al., 2010). A more recent report of cannabis seized in
Australia noted 14.88% THC (Swift et al., 2013). Recent research has suggested that
CBD may antagonize some negative effects of THC, such as anxiety (Niesink & van
Laar, 2013).
CB1 receptors are located on pre-synaptic terminals of both excitatory and inhibitory
neurons, as well as on glial cells, including astrocytes, microglia, and oligodendrocytes
(e.g., Domenici et al., 2006; Pazos et al., 2005). The eCB system includes the primary
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ligands anandamide (AEA) and 2-AG, which also bind CB1 (Mechoulam & Parker,
2013). After AEA interacts with CB1 at the pre-synaptic terminal, it is degraded by the
enzyme fatty acid amide hydrolase (FAAH) (Ho & Hillard, 2005). Thus, higher levels of
FAAH are typically associated with lower levels of eCBs (Giang & Cravatt, 1997).
From prenatal stages through adulthood, the eCB system influences
neurodevelopment (e.g., Aguado et al., 2006; Berghuis et al., 2007; Mulder et al., 2008;
Schneider et al., 2008; Chadwick et al., 2013). Activation of CB1 receptors can initiate a
signal transduction pathway that affects developmental processes, such as synaptic
plasticity, cell migration, axon guidance, and neuronal growth (Pazos et al., 2005;
Mechoulam & Parker, 2013; Melis et al., 2014; Zhou et al., 2014). The eCB system is
dispersed throughout the brain and undergoes dynamic changes throughout
neurodevelopment (Chadwick et al., 2013). CB1 receptors are highly expressed in the
PFC, cingulate cortex, hippocampus, amygdala, basal ganglia, and cerebellum, with
relatively low levels in the brainstem (Herkenham et al., 1990; Glass et al., 1997;
Mackie et al., 2005; Svizenska et al., 2008). While distribution of CB1 receptors stays
relatively constant across development, density is altered over time (Glass et al., 1997);
expression of CB1 mRNA and CB1 density and binding are highest during puberty
onset and adolescence, decreasing by adulthood (Ellgren et al., 2008; Schneider, 2008;
Heng et al., 2011; Chadwick et al., 2013; Higuera-Matas et al., 2015). This pattern is
particularly evident in the medial PFC, cingulate cortex, and insula, which demonstrate
the most dramatic and progressive decrease in CB1 expression across adolescence
(Heng et al., 2011). This decline in CB1 levels occurs in tandem with an increase in
AEA and decrease in 2-AG within the PFC (Ellgren et al., 2008). These differences in
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eCB activity across adolescence, particularly in maturing prefrontal regions, indicate a
role for this system in the neurodevelopmental processes occurring during this period.
Therefore, age-related changes in eCB functioning indicate that adolescents and
emerging adults may be at greatest risk to incur the negative consequences of cannabis
exposure (Higuera-Matas et al., 2015).
The eCB system, among other functions (e.g., sleep, pain, memory, feeding, and
inflammation), modulates mood and stress response. Indeed, genetic variants in the
eCB system, including multiple FAAH and CNR1 (gene coding for CB1) single
nucleotide polymorphisms, are associated with both subclinical depressive symptoms
and mood disorders in humans (Maple et al., in press; Barrero et al., 2005; Monteleone
et al., 2010; Mitjans et al., 2013). Moreover, several rodent studies have revealed that
increases in eCB activity elicit antidepressant and anxiolytic responses, while decreases
in activity lead to depression (Martin et al., 2002; Hill et al., 2005; Hill & Gorzalka, 2005;
Gobbi et al., 2005; Bortolato et al., 2007; Naidu et al., 2007; Serra & Fratta, 2007;
Adamczyk et al., 2008; McLaughlin & Gobbi, 2012). Steady eCB tone in the mPFC
prevents unnecessary limbic and HPA activation, promoting positive emotionality and
healthy coping responses to stress (McLaughlin, Hill, & Gorzalka, 2014). However,
under chronic, unpredictable stress, eCB tone in the mPFC can decrease, leading to
HPA hyperactivation. Indeed, this heightened HPA activity increases vulnerability to
anxiety and mood disorders (McLaughlin et al., 2014). This suggests a crucial role for
the eCB system in modulating frontolimbic activity in response to stress.
More specifically, evidence suggests that the eCB system is associated with facial
emotion processing. Studies have demonstrated that both FAAH (Hariri et al., 2008)
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and CNR1 (Chakrabarti et al., 2006) genotypes modulate brain activation to emotional
faces. Recognizing and interpreting facial expressions is a critical aspect of functioning
in human social networks. Facial expressions provide information about an individual’s
emotional state, and interpretation of these expressions by others can elicit an
emotional state in response (Phillips et al., 2003; Bourke et al., 2010). Therefore, it is
possible that any inaccuracy in identifying facial emotions may negatively influence
one’s affective state and emotional well-being (Phillips et al., 2003). In addition, mood
may bias one’s appraisals regarding facial emotions, therefore perpetuating a cycle of
appraisals impacting emotional responses, which in turn influence further appraisals
(e.g., Mogg et al., 2000; Joormann & D’Avanzato, 2010; Duque & Vazquez, 2015). In
fact, abnormal facial emotion processing is common in those with psychiatric disorders,
including major depressive disorder (MDD), bipolar disorder, social anxiety disorder,
and schizophrenia (e.g., Marwick & Hall, 2008; Morris et al., 2009; Bourke et al., 2010;
Stuhrmann et al., 2011; Staugaard, 2010; Samame, 2013).
Cannabis & Affective Processing
Considering the critical role the eCB system plays in modulating mood, and its
apparent role in processing facial emotions, it is unsurprising that both acute and
chronic exposure to exogenous cannabinoids, including THC and CBD, can alter
affective functioning. Multiple studies have found that acute THC administration
significantly impairs participants’ emotion identification abilities (Ballard et al., 2012;
Bossong et al., 2013; Hindocha et al., 2015), while CBD enhances accuracy (Hindocha
et al., 2015). Acute THC administration affects neural activation to emotional faces in
limbic (Phan et al., 2008; Bhattacharyya et al., 2010; Bossong et al., 2013), temporal
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(Fusar-Poli et al., 2009), frontal, parietal, and occipital (Fusar-Poli et al., 2009; Bossong
et al., 2013) areas. In response to emotional faces, CBD impacts activity in the left
amygdala, anterior and posterior cingulate cortices, anterior parahippocampal gyrus, left
middle occipital gyrus, and the cerebellum (Fusar-Poli et al., 2009; Bhattacharyya et al.,
2010). While some have found acute THC (Gorka et al., 2015) and CBD (Fusar-Poli et
al., 2010) to impact frontolimbic connectivity, others have found no effect (Fusar-Poli et
al., 2010). Cannabis smoking, which typically has substantially higher levels of THC
compared to CBD (Mehmedic et al., 2010), leads to poorer acute emotion recognition
(Clopton et al., 1979). Therefore, the current literature suggests that acute THC and
CBD impact many frontolimbic and associated areas with high eCB activity during facial
emotion processing.
Chronic cannabis exposure is associated with long-term affective and mood
problems. Cannabis users score higher on measures of anxiety and depression
compared to non-using controls (Troisi et al., 1998; Dorard et al., 2008; Medina &
Shear, 2007; Medina et al., 2007; Wright et al., under review). In fact, cannabis use has
a high rate of comorbidity with anxiety and mood disorders in both adolescents (e.g.,
McGee et al., 2000; Wittchen et al., 2007; Dorard et al., 2008) and adults (e.g., Troisi et
al., 1998; McGee et al., 2000; Agrawal et al., 2011; Lev-Ran et al., 2013). A substantial
number of studies suggest that cannabis use increases one’s risk for subsequently
developing affective disorders, especially if use begins in early adolescence (e.g.,
Bovasso, 2001; Patton et al., 2002; Rey & Tennant, 2002; Hayatbakhsh et al., 2007;
van Laar et al., 2007; de Graaf et al., 2010; Fairman & Anthony, 2012; Rasic et al.,
2013). Yet, other studies report anxiety and/or depression predicting later cannabis use
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(e.g., Wittchen et al., 2007). Thus, the relationship between cannabis and affect is
complicated and likely nuanced, especially given that many people reportedly use
cannabis to ameliorate internalizing symptoms, such as depression and anxiety (Boys
et al., 2001; Walsh et al., 2013). One mechanism underlying mood symptoms in
cannabis users may be damage to the affective neural network, resulting in deficits in
basic affective processing such as facial emotion processing.
A limited number of studies have investigated the relationship between chronic
cannabis use and facial emotion processing. The available evidence suggests that
cannabis users are significantly slower (Platt et al., 2010) and less accurate (Hindocha
et al., 2014; Bayrakci et al., 2015) in identifying emotions compared to controls. Further,
the ability of cannabis users to discriminate whether two faces show the same emotion
is reduced (Bayrakci et al., 2015). Findings from another group suggest that lower levels
of cannabis use might not be related to facial emotion processing, while more frequent
and recent cannabis use is associated with affective processing deficits (Huijbregts et
al., 2014). Chronic cannabis use has been associated with blunted ACC (Gruber et al.,
2009) and amygdala (Gruber et al., 2009; Cornelius et al., 2010) activation to negative
facial emotions, while in younger (14 years of age) cannabis users, amygdala activation
is increased (Spechler et al., 2015).
Cannabis Use and Brain Structure Associated with Affective Processing
Morphometry Studies. Facial emotion processing is a complex process, recruiting
many visual, limbic, temporoparietal, and prefrontal areas, as well as the cerebellum
and putamen (Ishai et al., 2005; Fusar-Poli et al., 2009; Said et al., 2011). Further,
many regions involved in facial emotion processing are high in CB1 receptor density,
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including the PFC, cingulate cortex, amygdala, hippocampus, and cerebellum. Chronic
cannabinoid exposure is associated with CB1 receptor downregulation in areas
associated with affect, including cortical regions (McKinney et al., 2008; Hirvonen et al.,
2012), the hippocampus, and cerebellum (Villares, 2007; McKinney et al., 2008). This
downregulation of CB1 receptors is likely one mechanism by which long-term cannabis
use can impact affective processing differentially from acute exposure.
Although some studies have examined functional brain relationships underlying
facial emotion processing in cannabis users, no known studies have investigated
structural relationships associated with these differences. Yet, several researchers have
examined basic brain structural differences related to cannabis use. Indeed, many of
these structural differences have been found in regions classically associated with
emotional face processing. Cannabis users have exhibited volumetric differences in the
mOFC (Churchwell et al., 2010; Cheetham et al., 2012; Batistella et al., 2014; Price et
al., 2015), total PFC (Medina et al., 2009), and fusiform gyrus (Jarvis et al., 2008). Only
one known study has investigated superior temporal gyrus volume in cannabis users
compared to non-users, yielding no difference between groups in either the right or left
superior temporal gyrus (DeLisi et al., 2006). Cannabis use has also been associated
with volume differences in subcortical affective regions such as the amygdala (Yucel et
al., 2008; McQueeny et al., 2011; Schacht et al., 2012; Cousijn et al., 2012; Gilman et
al., 2014; Pagliaccio et al., 2015), hippocampus (Matochik et al., 2005; Medina et al.,
2007a; Yucel et al., 2008; Ashtari et al., 2011; Demirakca et al., 2011; Schacht et al.,
2012; Cousijn et al., 2012; Solowij et al., 2013), and cerebellum (Jarvis et al., 2008;
Medina et al., 2010; Solowij et al., 2011; Cousijn et al., 2012; Batistella et al., 2014;
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Nurmedov et al., 2015). Most studies in emerging adult samples have demonstrated
decreased volumes across brain regions in association with cannabis use (eg, Matochik
et al., 2005; Yucel et al., 2008; Churchwell et al., 2010; Ashtari et al., 2011; Demirakca
et al., 2011; Schacht et al., 2012; Cousijn et al., 2012; Solowij et al., 2013; Batistella et
al., 2014; Price et al., 2015; Pagliaccio et al., 2015).
Some studies have reported increased volumes in association with cannabis use
(e.g., Medina et al., 2009; Medina et al., 2010; McQueeny et al., 2011). However, these
samples were comprised exclusively of younger adolescents (eg, 16-18 years). In these
studies, increased volumes were associated with functional deficits such as poorer
executive functioning and increased internalizing symptoms. The authors of these
studies hypothesize that cannabis may interfere with significant synaptic pruning
occurring during adolescence (Medina et al., 2009; Medina et al., 2010; McQueeny et
al., 2011; Lisdahl et al., 2014). Further, gender may moderate these findings;
adolescent females appear to be particularly vulnerable to the impact of cannabis on
PFC and amygdala volumes (Medina et al., 2009; McQueeny et al., 2011). Despite this
substantial literature, some studies have reported null findings for each of these brain
regions (eg, Tzilos et al., 2005; Medina et al., 2007b; Ashtari et al., 2011; Cousijn et al.,
2012; Mashhoon et al., 2015; Pagliaccio et al., 2015; Smith et al., 2015; Lorenzetti et
al., 2015; Price et al., 2015; Weiland et al., 2015). Thus, more research is needed to
clarify how gender might moderate the relationship between cannabis use and PFC,
limbic, and cerebellar volumes.
White Matter Integrity. As CB1 receptors are present on axons and
oligodendrocytes (Domenici et al., 2006; Pazos et al., 2005), which comprise white
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matter, exogenous cannabinoids may alter white matter functioning. Several diffusion
tensor imaging (DTI) studies have found associations with cannabis use and white
matter integrity in regions throughout the brain (e.g., Gruber & Yurgelun-Todd, 2005;
DeLisi et al., 2006; Arnone et al., 2008; Ashtari et al., 2009; Bava et al., 2009; Allin et
al., 2009; Bava et al., 2010; Gruber et al., 2011; Zalesky et al., 2012; Bava et al., 2013;
Jacobus et al., 2013a; Jacobus et al., 2013b). Of particular note, Shollenbarger and
colleagues (2015) found an association between cannabis use and decreased white
matter integrity in the corpus callosum forceps minor, uncinate fasciculus, and anterior
thalamic radiations (ATR). As the CC forceps minor, uncinate fasciculus, and ATR
connect frontolimbic regions (Catani & Thiebaut de Schotten, 2012), reduced integrity in
these tracts may be of particular relevance to affective processing. Reduced uncinate
integrity has been associated with major depression (Bracht et al., 2015; Taylor et al.,
2007; Cullen et al., 2010; Dalby et al., 2010; Carballedo et al., 2012; Zhang et al., 2012)
and poorer facial emotion recognition (Fuije et al., 2008). Similarly, several studies have
associated integrity in the ATR (Henderson et al., 2013; Bessette et al., 2014; Lai & Wu,
2014, Bracht et al., 2015) and CC forceps minor (e.g., Alves et al., 2014; Serafini et al.,
2014) with mood disorders. Thus, considering the association that the uncinate, ATR,
and forceps minor have with affective disorders, it is possible they are involved in
affective processing in cannabis users. Consistent with this, Shollenbarger and
colleagues (2015) found that increased subclinical depressive symptoms in cannabis
users were associated with decreased integrity in bilateral ATR and right uncinate
fasciculus. However, more research is needed to determine if these tracts are
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associated with specific aspects of affective processing, such as identifying facial
emotions.
Gender Differences
Evidence indicates that male and female brains may process affective information
differently. Women have twice the rate of affective disorders as men (e.g., Gater et al.,
1998), and research findings suggest that healthy females are generally more accurate
at identifying facial emotions compared to males (Kret & De Gelder, 2012). Further,
males and females appear to recruit different networks while processing emotional
faces (Killgore & Yurgelun-Todd, 2001; Killgore et al., 2001; Killgore & Yurgelun-Todd,
2004; Whittle et al., 2011). Although the literature is not wholly consistent, females tend
to exhibit increased temporal, ACC, and limbic activation while males demonstrate
increased frontal and parietal activation to emotional faces (Hall et al., 2004; Kempton
et al., 2009; Whittle et al., 2011). In addition, female affective circuitry may be more
susceptible to the negative effects of cannabis use. For instance, compared to males,
adolescent female rats exposed to THC are more vulnerable to its anxiety and
depression producing properties (Rubino et al., 2008). In humans, female cannabis
users have exhibited disadvantages in PFC and amygdala volumes compared to their
male counterparts (Medina et al., 2009; McQueeny et al., 2011). Additionally within
females compared to males, increased CB1 desensitization to THC is observed within
frontolimbic regions, including the PFC, amygdala, and hippocampus (Crane et al.,
2013). Thus, cannabis-using females may process facial emotions differently from male
users, and this may be related to underlying brain structure in frontolimbic regions.
Aims and Hypotheses
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Despite evidence that chronic cannabis use may impact facial emotion processing in
adolescents and emerging adults, few studies have examined affective processing in
regular cannabis users and whether these relate to structural abnormalities in the
affective processing network. Thus, the current study seeks to elucidate these
relationships.
Primary Aims. (1) Cannabis Use and Affective Processing. We will investigate
whether increased cannabis use or cannabis x gender predict affective processing and
mood symptoms in adolescents and emerging adults. Specifically, we will examine
whether these variables predict (a) facial emotion processing and (b) depressive
symptoms. Based on the aforementioned literature, we hypothesize that cannabis users
will have impaired emotional processing and increased depressive symptoms compared
to non-users. It is predicted that females will be more susceptible to the potential effects
of cannabis on (a) affective processing and (b) depressive symptoms compared to
males.
(2) Cannabis Use and Brain Structure. We will assess whether cannabis use and
cannabis x gender are associated with abnormal brain structure in regions underlying
affective processing. (a) We will investigate whether cannabis use and cannabis x
gender predict volumes of regions implicated in affective processing, including the
bilateral medial orbital frontal cortex (mOFC), lateral orbital frontal cortex (lOFC), rostral
ACC (rACC), caudal ACC (cACC), Pars triangularis, superior temporal gyrus, fusiform
gyrus, amygdala, hippocampus, and cerebellum. Based on other studies with a similar
mean age, we hypothesize that increased cannabis use will be associated with
decreased gray matter volumes in prefrontal regions, superior temporal gyrus, fusiform
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gyrus, amygdala, and hippocampus, as well as increased cerebellar volumes.
Additionally, it is predicted that greater cannabis use in females will be associated with
the most marked volumetric relationships. (b) We will also explore whether cannabis
use and cannabis x gender predict white matter integrity in major frontolimbic tracts
involved in affective processing: R/L uncinate fasciculus, R/L anterior thalamic
radiations, and corpus callosum forceps minor. We hypothesize that higher levels of
cannabis use will be associated with decreased white matter integrity in these regions. It
is additionally predicted that females with more cannabis use will have the greatest
reduction in white matter integrity.
Secondary Aim. Once we determine regions that are associated with either
cannabis or cannabis x gender, we will determine if those areas predict (a) emotional
processing and (b) depressive symptoms within the cannabis user group. We
hypothesize that brain structure will predict affective processing and depressive
symptoms within cannabis users.
Method
Participants
Participants included 77 (two of these did not complete the MRI scan due
claustrophobia) cannabis using and non-using adolescents and emerging adults ages
16-25 years, recruited from a larger parent study (R01 DA030354).
Recruitment. Individuals were recruited from the community. Flyers were posted
around universities, cafes, bars, headshops, recreation centers and festivals. Best
attempts were made to recruit an ethnically representative sample balanced for gender.
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Inclusion/Exclusion Criteria. Inclusion criteria. Inclusion criteria for cannabis use.
Used cannabis at least 10 times in past three months or at least 50 times in life.
Inclusion criteria for non-using controls. Used cannabis fewer than 50 times in life and
fewer than five times in the past year. Exclusion criteria (both groups). Non-English
speaker, left-handed, has non-removable metal (or any other MRI contraindication),
younger than 16 years of age, older than 25 years of age, prenatal alcohol (>6 drinks
per week or >4 per day) or nicotine exposure, birth complications, premature birth (<33
weeks gestation), no neurological disorders (ie, seizures, migraines, tumors,
chemotherapy, multiple sclerosis, movement disorders), head trauma with >2 minute
loss of consciousness, learning disability, intellectual disability, vision or hearing
impairments, major health problems, independent DSM-IV psychological disorder
diagnosis (aside from substance use disorder), current use of psychoactive medication,
using more than 10 cigarettes per day, heavy other drug use (>25 lifetime uses of noncannabis drugs), possible pregnancy, failure to remain abstinent from substances
throughout the study (as indicated by positive urine toxicology and/or continuous sweat
patch testing).
In order to assess inclusion and exclusion criteria, screening included both an initial
and a detailed phone screen, each with both the youth participant and a parent/guardian
(required for ages 16-17; highly preferable for ages 18-25).
Screening. Initial Screening. When a potential participant called in response to an
advertisement, study staff obtained verbal consent/assent to conduct a 5-10 minute
phone screen (if youth was younger than 18, study staff gained permission from a
parent/guardian) with each the parent and youth separately to determine basic eligibility
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with non-sensitive questions (eg, age, ethnicity, MRI contraindications, vision and
hearing problems, yes/no questions about psychiatric history and yes/no questions
about substance use).
Detailed Screening. Before conducting the 45-minute detailed phone screen, study
staff obtained written consent/assent from participants and parents. Comprehensive
substance use history (lifetime) was obtained from youth with the Customary Drinking
and Drug Use Record (CDDR) (Brown et al., 1998; Stewart and Brown, 1995).
Information regarding youth psychiatric history was gathered by administering the Mini
International Psychiatric Interview (MINI) (Sheehan et al., 1998) to youth and parents.
Youth and parents were informed if ineligible and each paid $20 upon completion of the
detailed screen. To maintain study integrity, specific reasons for ineligibility were not
disclosed to participants.
Procedure
Eligible participants attended five study sessions over the course of four weeks.
Sessions 1-3 were weekly sessions consisting of drug testing and brief
neuropsychological testing. One week after Session 3, Sessions 4 and 5 were
conducted within 24-48 hours of each other. Session 4 included a 3-hour
neuropsychological battery, while Session 5 consisted of MRI scanning.
Verifying abstinence. Biological measures. Participants were expected to remain
abstinent from alcohol and drugs throughout the course of the study in order to prevent
acute intoxication. Thus, all participants were monitored for substance abstinence
during each of five study sessions. At each session, participant abstinence was
evaluated using urine toxicology, specifically the ACCUTEST SplitCup 10 Panel drug
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test, which measured whether someone was positive or negative for amphetamines,
barbiturates, benzodiazepines, cocaine, ecstasy, methadone, methamphetamines,
opiates, PCP, and THC. Urine samples were also used to measure cotinine (metabolite
of nicotine) levels with NicAlert. In addition to the urine toxicology, continuous sweat
toxicology was conducted with the PharmChek Drugs of Abuse Patch, which tested for
cocaine, benzoylecgonine, heroin, 6MAM, morphine, codeine, amphetamines,
methamphetamine, THC, and phencyclidine. Furthermore, at each session, participants
underwent breathalyzer testing for recent alcohol use. Participants who tested positive
for any drugs, or who had a blood alcohol concentration of >.000 directly prior to
Session 4 (extended neuropsychological battery) and Session 5 (MRI scanning) were
removed from the study.
Measures
Demographic Information. Participants completed a background questionnaire
outlining demographic variables including age, gender, ethnicity, self and biological
parents’ educations, incomes, and employments, marital status, history of medical or
neurological illness, psychological disorders or use of psychiatric medication, and
learning disability.
Substance use. During each session, participants were asked to report the last time
they used alcohol, marijuana, cigarettes, or other drugs. In addition, at Session 3,
participants were asked to complete the Timeline Follow Back (TLFB; Sobell & Sobell,
1992). This is a highly reliable and valid measure of past year substance use, using
holidays and other memory cues. As part of completing the TLFB, participants were
asked to report the quantity of specific substances (e.g., alcohol, cannabis, nicotine,
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etc.) used on each day during the past year. Substance use was measured in standard
units (e.g., joints for cannabis). Lifetime and past 3-month substance use was measured
using the Customary Drinking and Drug Use Record (CDDR), which also assesses
withdrawal symptoms, DSM-IV abuse and dependence criteria, and substance-related
difficulties (Brown et al., 1998; Stewart and Brown, 1995).
Self-reported Mood. Participants completed the Beck Depression Inventory-II (BDIII; Beck et al., 1996) at Session 4. This measure contains 21 items measuring past twoweek depressive symptoms on a 0-3 point scale. Total scores indicate either “minimal”
depression (0-13), “mild” depression (14-19), “moderate” depression (20-28), and
“severe” depression (29-63). Independent depressive disorders were excluded as part
of the larger imaging study.
Affective Processing. During Session 4, participants completed an affective battery
(PennCNP) containing three facial emotion processing tasks of interest to the current
analysis: Emotion Recognition, Emotion Discrimination, and Emotional Acuity tasks. In
Emotion Recognition, participants were presented with a series of faces (shown
individually) and instructed to identify which emotion each face was expressing.
Possible answer choices included happy, sad, anger, fear, and no emotion. The facial
stimuli are described in Gur et al. (2002) and Pinkham et al. (2008). In the Emotion
Discrimination task, participants were presented with pairs of faces, one pair for each
trial. Each pair of faces contained two pictures of the same individual, with or without a
subtle (computer-generated) change in facial expression, which may or may not have
indicated a difference in intensity between the two facial emotions. During each trial, the
participant had to decide which picture expressed the specified emotion (happy or sad)
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more intensely, or whether they were equal. In the Emotional Acuity task, participants
were presented with one face per trial. Faces were randomly presented and participants
were instructed to rate the facial expression’s emotional valence on a 7-point scale: very
sad, moderately sad, somewhat sad, neutral, somewhat happy, moderately happy, or
very happy. Facial stimuli for the Emotion Discrimination and Emotional Acuity tasks are
described in Erwin et al. (1992). As normative scores are not available for this battery,
all analyses were conducted with raw scores.
MRI Data Acquisition. Participants were scanned on a 3T GE scanner at Medical
College of Wisconsin (MCW) during Session 5, which was completed within 24-48
hours of Session 4 (when affective measures were obtained). Structural Image
Acquisition. This took approximately 15 minutes. A T1-weighted, 3-D anatomical brain
scan was obtained with a modified driven equilibrium Fourier transform (MDEFT)
sequence (TMD=1.1 s, TR=13 ms, FOV=25.6 x 19.2 x 19.2 cm., matrix 256 x 192 x 96
pixels, flip angle=20 degrees). Diffusion Tensor (DTI) Image Acquisition. DTI was
obtained using 48 diffusion directions with b ≈ 700s/mm2 (FOV= 25.6 cm, 128 x 128
matrix, resolution=4x4x4 mm, TR = 9,300 ms, TE = 81.4 ms (minimum), flip angle 90 ̊.
MRI Processing. Image Preprocessing. Structural images were initially
preprocessed using the Analysis of Functional Neuroimages (AFNI) software package.
This sequence included converting 2D slice data into a 3D dataset (BRIK and HEAD
files). This file was then converted into a file readable by FreeSurfer (.mgz). Using
FreeSurfer software, all T1-weighted 3D anatomical datasets underwent motion
correction, non-parametric non-uniform intensity normalization, MNI transformation,
removal of non-brain materials, and skull-stripping. This was followed by whole-brain
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segmentation of white and gray matter and registration of anatomical brain regions.
Automatic subcortical segmentation took place in six steps, including registration to a
template, canonical normalization, canonical registration, neck removal, registration
w/skull, and subcortical labeling. Bilateral cortical ROIs (mOFC, rACC, cACC, Pars
triangularis, Pars orbitalis, OFC, superior temporal gyrus, fusiform gyrus) were
parcellated using the Desikan-Killiany atlas (Desikan et al., 2006) in FreeSurfer. This is
a gyral-based atlas; regions include a gyrus plus adjacent sulci. Using these ROIs,
regional cortex volumes (in cubic millimeters) were obtained. In the current analysis,
Pars orbitalis and OFC were combined to create the lateral OFC (lOFC) region. All
automated FreeSurfer steps were inspected for processing errors, and manual edits
were made as needed. For each case, automatic segmentation and parcellation masks
were manually edited for accurate segmentation, using multiple views for visual
inspection.
DTI Processing. Following whole-brain segmentation, the software program, Tracts
Constrained by Underlying Anatomy (TRACULA) (within FreeSurfer) was used to
analyze tractography data. TRACULA is a global probabilistic tractography program
allowing reconstruction of white matter pathways from diffusion tensor images. This
yields measures of white matter integrity, including fractional anisotropy (FA) and mean
diffusivity (MD) (Yendiki et al., 2011). Each image underwent the following
preprocessing steps: (1) Image Corrections (e.g., for B0 inhomogeneities, eddy
currents, and simple head motion), (2) Further head motion correction, (3) Intra-subject
and Inter-subject registration (4) Mask creation (White matter is extracted from
FreeSurfer’s segmentation and parcellation and combined into a mask), (5) Tensor fit,
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(6) Estimation of pathway priors (the atlas data was combined with the individual’s own
masks). Following this preprocessing, a ball-and-stick model of diffusion was fitted to
the images. After diffusion measures in each voxel were determined by Markov Chain
Monte Carlo sampling, likelihood of the locations of uncinate fasciculus, ATR, and
corpus callosum forceps minor pathways within each individual were established. From
these estimated pathways, statistics on diffusion measures (average weighted FA and
MD) within each individual were extracted. We performed group analyses along the
entire corpus callosum forceps minor, bilateral uncinate fasciculus, and bilateral anterior
thalamic radiations tracts. For nine of these participants, forceps minor could not be
adequately reconstructed in TRACULA. Thus, they were excluded from the regressions
investigating forceps minor FA and MD.
Data Analysis
Preliminary Analysis. All analyses were conducted in the statistical program SPSS.
For each primary aim, demographic and other drug use was examined using ANOVA
(or Mann-Whitney for any variables not normally distributed) and Chi-Square analyses
to detect differences between cannabis users and non-users. Variables that either
differed between groups or have known relationships with affective processing or brain
structure were entered as covariates. For Aim 1, these included gender, past year
alcohol use, and past year nicotine use. Aim 2 included these covariates as well as
intracranial volume for volumetric analyses.
Principal Components Analysis (PCA) for Emotional Processing Tasks. We
conducted three principal components analyses (PCA) to extract components from each
of the Emotion Recognition, Emotion Acuity, and Emotion Discrimination tasks.
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Accuracy and response time variables were selected for each task and entered into
PCA (see Tables 2, 3, 4).
Primary Analysis. Aim 1. Multiple regressions (including appropriate covariates)
were used to examine whether past year cannabis use and cannabis x gender predicted
(a) emotional processing (as defined by components extracted from PCA) and (b) BDI-II
scores. Aim 2. To determine the relationship between past year cannabis use, cannabis
x gender, and brain structure: (a) Multiple regressions (including appropriate covariates)
were used to predict bilateral mOFC, lOFC, Pars triangularis, superior temporal gyrus,
fusiform gyrus, rACC, cACC, amygdala, hippocampus, and cerebellum volumes from
past year cannabis use and cannabis x gender. (b) Multiple regressions (including
appropriate covariates) were used to predict fractional anisotropy (FA) and mean
diffusivity (MD) of the corpus callosum forceps minor, bilateral uncinate fasciculus, and
bilateral anterior thalamic radiations from past year cannabis use and cannabis x
gender. Main effects and covariates were entered into the first block; interaction
variables were included in the second block. In order to assess if any participants
disproportionately influenced the regression models, DFBETA analyses for past year
cannabis use and cannabis x gender were conducted. One outlier for past year
cannabis use was observed in predicting depressive symptoms; thus it was removed
from the model. Results are reported with outliers removed. False Discovery Rate
(FDR) correction (Benjamini & Hochberg, 1995 method) was conducted in Aims 1, 2a,
and 2b. In aim 2a, FDR corrections were run separately for subcortical volume and
cortical volume variables within each brain hemisphere (R/L) and white matter integrity
variables. Additionally, f2 was used to assess effect sizes for multiple regression
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analyses (small= 0.02-0.14, medium= 0.15-0.34, and large= >0.35) (Cohen et al.,
2003).
Secondary Analysis: Brain-Behavior Relationships. We conducted brainbehavior analyses on brain regions that were significantly associated with past year
cannabis use or cannabis x gender. For those regions that differed, we ran Pearson
correlations within the cannabis group to determine whether brain abnormalities were
related to (a) emotional processing and (b) BDI-II scores. For all analyses, significance
was determined if p <0.05.

Results
Preliminary Results
Aim 1 Subgroup: Demographic Information (see Table 1). ANOVAs and chisquare tests revealed no significant difference between cannabis users and non-users
in age (F(1,75)= 1.17, p= .28), race (χ2(5)= 5.30, p=.38), ethnicity (χ2(2)= .92, p=.63),
gender (χ2(1)= 2.50, p=0.11), and reading ability (F(1,75)= 1.81, p= .18).
Aim 1 Subgroup: Drug Use Information. Cannabis users and non-users
significantly differed on measures of past year cannabis use (F(1,75)= 24.54, p<.01),
past year alcohol use (F(1,75)= 15.18, p<.01) and past year nicotine use (F(1,75)= 7.61,
p<.01). Past year alcohol and nicotine use were included as covariates in the
regressions.
Aim 2 Subgroup: Demographic Information (see Table 1). ANOVAs and chisquare tests revealed no significant difference between cannabis users and non-users
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in age (F(1,73)= 0.98, p= .32), race (χ2(5)= 5.68, p=.34), ethnicity (χ2(2)= .92, p=.63),
gender (χ2(1)= 1.88, p=0.24), and reading ability (F(1,73)= 1.54, p= .22).
Aim 2 Subgroup: Drug Use Information. Cannabis users and non-users
significantly differed on measures of past year cannabis use (F(1,73)= 22.89, p<.01),
past year alcohol use (F(1,73)= 14.58, p<.01), and past year nicotine use (F(1,73)=
7.69, p<.01). Past year alcohol and nicotine use were included as covariates in the
regressions.
Principal Components Analysis. Three principal components analyses (PCA) were
conducted to reduce variables from the each of the tasks (Emotion Recognition, Acuity,
and Discrimination) in the PennCNP affective battery. Variables with loadings > 0.6
were considered to define a component. Emotion Recognition. For the Emotion
Recognition task, nine variables were subjected to PCA with varimax rotation. This
yielded four components meeting Kaiser’s criterion (eigenvalues >1). The following
components were obtained (see Table 2): Recognition Time (29.54% of variance),
Anger/Fear Correct (14.15% of variance), Sad Correct (13.91% of variance), and Happy
Correct (12.57% of variance). These components accounted for 70.17% of the total
variance observed in the Emotion Recognition variables. Emotional Acuity. Twelve
variables were subjected to PCA for the Emotional Acuity task, yielding three
components meeting Kaiser’s criterion (eigenvalues >1). Components included Acuity
Time (34.32% of variance), Acuity Neutral (28.15% of variance), and Acuity Intensity
(13.08% of variance) (see Table 3). Together, these components explained 75.55% of
the variance observed. Emotion Discrimination. For the Emotion Discrimination task,
eight variables underwent PCA with varimax rotation. Two components meeting

	
  

23

	
  
Kaiser’s criterion (eigenvalues >1) were obtained (see Table 4): Discrimination Time
(46.72% of variance) and Discrimination Correct (33.86% of variance). These
components accounted for 80.58% of the total variance.

Primary Results (see Table 5 for significant findings)
All regions of interest demonstrating a significant relationship with either cannabis
use or cannabis x gender are represented in Figure 1. Covariates included gender, past
year alcohol use, and past year nicotine use. Intracranial volume (ICV) was included as
an additional covariate in sMRI regressions.
Behavioral Outcomes. Cannabis. Past year cannabis use did not significantly
predict Acuity Time [t (67) = .07, beta=.01, p=.95], Acuity Intensity [t (67) = 1.12, beta=
.14, p=.30], Recognition Time [t (71) = -.34, beta= -.04, p=.73], Anger/Fear Correct [t
(72) = 1.17, beta= .14, p=.25], Happy Correct [t (72) = .40, beta= .05, p=.69], Sad
Correct [t (72) = .13, beta=.02, p=.90], Discrimination Time [t (72) = -.55, beta=-.07,
p=.58], Discrimination Correct [t (72) = -.64, beta=-.08, p=.53], or depressive symptoms
[t (71) = .84, beta=.11, p=.40]. Increased cannabis use was significantly associated with
increased Acuity Neutral scores [t (67) = 2.02, beta= .25, p<.05, f2=.06, FDR-corrected:
p=.47] (see Figure 2). Cannabis*Gender. Cannabis use and gender did not interact to
predict Acuity Time [t (66) = .51, beta=.06, p=.62], Acuity Intensity [t (66) = -.54, beta= .07, p=.59], Acuity Neutral [t (66) = -.26, beta= -.03, p=.80], Recognition Time [t (71) = .17, beta=-.02, p=.87], Anger/Fear Correct [t (71) = .70, beta= .09, p=.49], Happy
Correct [t (71) = -1.50, beta= -.18, p=.14], Sad Correct [t (71) = .62, beta=.08, p=.54],
Discrimination Time [t (71) = 1.15, beta=.14, p=.25], and depressive symptoms [t (70) =
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-.19, beta=-.03, p=.85]. Cannabis and gender marginally interacted to predict
Discrimination Correct such that in females, greater cannabis use was associated with
lower Discrimination Correct scores; males exhibited the opposite pattern [t (71) = -1.93,
beta=-.23, p<.06]. Covariates. Gender significantly predicted Happy Correct, such that
females had higher scores on this component compared to males [t (72) = 2.17, beta=
.26, p= .03].
sMRI Outcomes. Cannabis. Past year cannabis use did not significantly predict left
hippocampus [t (69) = 1.08, beta=.10, p=.29], right hippocampus [t (69) = -.31, beta=.03, p=.76], left amygdala [t (69) = 1.28, beta=.13, p=.21], right amygdala [t (69) = -.34,
beta=-.04, p=.76], left cerebellum [t (69) = 1.24, beta=.11, p=.22], right cerebellum [t
(69) = 1.57, beta=.14, p=.12], right cACC [t (69) = -.84, beta=-.09, p=.40], left cACC [t
(69) = -1.19, beta=-.14, p=.24], right rACC [t (69) = .41, beta=.05, p=.68], right mOFC [t
(69) = -.08, beta=-.01, p=.94], left mOFC [t (69) = -.51, beta=-.05, p=.61], left lOFC [t
(69) = .29, beta=.03, p= .77], right pars triangularis [t (69) = -.85, beta=-.10, p=.40], left
pars triangularis [t (69) = -1.00, beta=-.12, p=.32], right fusiform gyrus [t (69) = .45,
beta=.04, p=.65], left fusiform gyrus [t (69) = -.28, beta=-.03, p=.78], and left superior
temporal [t (69) = 1.35, beta=.12, p= .18] volumes. Increased past year cannabis use
marginally predicted smaller right lOFC volumes [t (69) = -1.93, beta=-.18, p<.06].
Greater past year cannabis use significantly predicted smaller left rACC volumes [t (68)
= -3.26, beta=-.29, p<.01, f2= .11; FDR corrected: p= 0.01] and larger right superior
temporal volumes [t (69) = 2.27, beta=.19, p= .03, f2= .06; FDR corrected: p= 0.19] (see
Figure 3). Cannabis*Gender. Cannabis use and gender did not interact to predict left
hippocampus [t (68) = -1.04, beta=-.10, p=.30], right hippocampus [t (68) = .11,
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beta=.01, p=.91], left amygdala [t (68) = -.22, beta=-.02, p=.83], right amygdala [t (68) =
-.24, beta=-.03, p=.81], left cerebellum [t (68) = 1.06, beta=.10, p=.29], [t (68) = .17,
beta=.02, p=.86], right cerebellum [t (68) = .17, beta=.02, p=.86], right cACC [t (68) =
.30, beta=.03, p=.76], left cACC [t (68) = .69, beta=.08, p=.50], right rACC [t (68) = 1.54, beta=-.17, p=.13], right mOFC [t (68) = .53, beta=.05, p=.60], left mOFC [t (68) =
.84, beta=.08, p=.40], right lOFC [t (68) = .64, beta=.06, p=.53], left lOFC [t (68) = 1.12,
beta=.67, p=.27], right pars triangularis [t (68) = .23, beta=.03, p=.82], left pars
triangularis [t (68) = .18, beta=.02, p=.86], right fusiform gyrus [t (68) = -.24, beta=-.02,
p=.81], left fusiform gyrus [t (68) = .47, beta=.04, p=.64], right superior temporal [t (68) =
.98, beta=.08, p=.33], or left superior temporal [t (68) = -2.70, beta=-.26, p<.01] volume.
Cannabis use and gender significantly interacted to predict left rACC volumes, such that
only females demonstrated reduced volumes with increased cannabis use [t (68) = 2.14, beta=-.19, p=.04, f2= .07; FDR corrected: p=.25] (See Figure 4). Covariates.
Gender was significantly associated with left amygdala [t (69) = -2.13, beta=-.28, p=.04],
left cerebellum [t (69) = -2.78, beta=-.34, p<.01], and right cerebellum [t (69) = -3.12,
beta=-.37, p<.01] volumes, such that females exhibited smaller volumes compared to
males.
DTI Outcomes. Cannabis. Past year cannabis use did not significantly predict right
uncinate fasciculus FA [t (70) = .10, beta=.01, p= .92], right ATR FA [t (70) = -.08, beta=
-.01, p= .94], right ATR MD [t (70) = -.95, beta= -.11, p= .35], left uncinate fasciculus FA
[t (70) = -.01, beta=-.00, p= .99], left ATR FA [t (70) = .67, beta= .08, p= .50], left ATR
MD [t (70) = -1.06, beta= -.13, p= .29], forceps minor FA [t (61) = -.05, beta=-.01, p=
.96], or forceps minor MD [t (61) = -.84, beta=-.11, p= .40]. Cannabis use marginally
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predicted left uncinate MD [t (70) = -1.85, beta=-.22, p= .07]. Greater cannabis use was
significantly associated with reduced MD in the right uncinate fasciculus [t (70) = -2.00,
beta=-.24, p= .05, f2= .06; FDR corrected: p= .34] (see Figure 5). Cannabis*Gender.
Cannabis*Gender did not significantly predict right uncinate fasciculus FA [t (69) = 1.19,
beta=.15, p=.24], right uncinate fasciculus MD [t (69) = -.70, beta= -.08, p=.49], right
ATR FA [t (69) = .54, beta=.06, p=.59], right ATR MD [t (69) = -.57, beta=-.07, p=.57],
left uncinate fasciculus FA [t (69) = 1.22, beta=.15, p=.23], left uncinate fasciculus MD [t
(69) = -.45, beta=-.05, p=.65], left ATR FA [t (69) = .21, beta=.02, p=.83], left ATR MD [t
(69) = -.84, beta=-.10, p=.40], or forceps minor MD [t (60) = -.69, beta=-.09, p=.50].
Cannabis*Gender significantly predicted forceps minor FA, such that females
demonstrated increased FA with more use while the opposite pattern was observed in
males [t (60) = 2.06, beta=.26, p=.04, f2= .07; FDR corrected: p=.44] (see Figure 6).
Covariates. Increased past year nicotine use was significantly associated with reduced
right ATR FA [t (70) = -2.07, beta= -.24, p= .04]. Gender significantly predicted right [t
(70) = 2.27, beta= .27, p= .03] and left [t (70) = 2.42, beta=.28, p=.02] ATR MD, such
that females had higher values compared to males. Gender also significantly predicted
left uncinate MD [t (70) = 2.14, beta=.25, p= .04] and left ATR FA [t (70) = -2.70, beta= .31, p<.01], such that males had higher values relative to females.

Secondary Results (Brain-Behavior Relationships in Cannabis users)
Within cannabis users, smaller left rACC volumes were significantly associated with
lower Discrimination Correct scores [r= .37, p= .04] (see Figure 7). Since
cannabis*gender predicted left rACC volumes, the relationship between gender and left
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rACC was explored. Within female cannabis users, smaller left rACC volumes
significantly predicted lower Discrimination Correct scores [r= .68, p= .01]. Within male
cannabis users, no significant relationship was observed between left rACC volume and
Discrimination Correct scores [r= .31, p= .18]. No other affective measures were
significantly associated with left rACC, right superior temporal volumes, or right uncinate
fasciculus MD.
Discussion
To our knowledge, this is the first study to assess the dose-dependent relationships
between cannabis use, affective processing, and brain structure. Our first primary aim
was to examine the association between cannabis use, depressive symptoms, and
performance on an affective processing battery. Contrary to our predictions, we found
that greater past year cannabis use predicted higher Acuity Neutral component scores.
In the second primary aim, we investigated relationships between cannabis use and
brain structures previously shown to be associated with affective processing. Most
notably, increased past year cannabis use significantly predicted smaller left rACC
volumes. Gender moderated this relationship such that only females exhibited
significantly smaller left rACC volumes with increased cannabis use. Secondary
analyses revealed that within the cannabis-using group, decreased left rACC volumes
were significantly correlated with lower Discrimination Correct scores. This suggests
that cannabis-related differences in the left rACC are associated with functional deficits.
Past year cannabis use predicted larger right superior temporal volumes and lower MD
in the right uncinate fasciculus. Finally, a significant cannabis x gender interaction was
observed in the forceps minor, with females exhibiting increased FA with more use,
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while the opposite pattern occurred in males. The only relationship that survived
correction for multiple comparisons was the main effect of increased cannabis use
predicting smaller left rACC volumes.
Our finding that greater cannabis use predicted higher scores on one component,
Acuity Neutral, is, to our knowledge, the first report of chronic cannabis use being
related to improved performance on an emotional faces task. This was in contrast to our
hypothesis that chronic cannabis use would be associated with poorer affective
processing due to downregulation of CB1 receptors in brain regions regulating affect
(Hirvonen et al., 2012). In previous studies, cannabis users have exhibited deficits in
facial emotion processing, although literature in this area is sparse (Platt et al., 2010;
Hindocha et al., 2014; Huijbregts et al., 2014; Bayrakci et al., 2015). Hindocha et al.
(2014) found that cannabis users were more impaired than controls in recognizing static
facial emotions of moderate and higher intensity; this difference was not observed in
processing more subtle emotions (20% emotional). Further, using a dynamic facial
morphing task, Platt and colleagues (2010) found that cannabis users required a greater
intensity of emotion for correct identification. Our findings deviate from both of these
studies, in that cannabis use was not associated with more or less accurate intense
emotion identification (Acuity Intensity component), but was associated with improved
accuracy for subtle emotions (Acuity Neutral component). This may be due to
differences in task construction (e.g., static versus dynamic stimuli, providing wider
range of response options) across studies.
Another possible explanation is differences in cannabis exposure; mean use
amongst cannabis users was higher (25-27 uses per month) in both the studies by
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Hindocha et al. (2014) and Platt et al. (2010) compared to the current study (20 uses
per month). Thus, it is possible that emotional face processing deficits are only
observable in heavier (closer to daily) cannabis users. Some research suggests that
adolescents who engage in a low to moderate level of cannabis use (no more than
monthly) have improved interpersonal relations compared to those who abstain and
heavier users (Shedler & Block, 1990). This may provide insight into the higher Acuity
Neutral scores in the current study; 39.4% of the cannabis users in the current study
used monthly or less frequently in the past year. Further, cannabis samples can vary
widely in levels of THC and CBD (Swift et al., 2013), which may account for differences
across studies. As acute CBD has been shown to improve facial affect recognition at
moderate intensity (Hindocha et al., 2015), perhaps more participants in the current
study used cannabis higher in CBD compared with participants in studies by Platt et al.
(2010) and Hindocha et al. (2014). Future work will be needed in order to address this
possibility. However, as the relationship between cannabis use and Acuity Neutral in the
current study did not survive correction for multiple comparisons, it should be
interpreted with caution.
Our most robust finding was that greater cannabis use was associated with reduced
left rACC volumes, driven primarily by females. Null findings reported by other groups
(Cousijn et al., 2012; Lorenzetti et al., 2015) may be due to the gender distribution. This
finding is consistent with a recent report in young adult cannabis users with comorbid
ADHD (Lisdahl et al., in press). Further, earlier age of cannabis use onset has been
associated with reduced right rACC thickness within a sample of alcohol and cannabis
using adolescents (Jacobus et al., 2014). Additionally, research amongst psychosis
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patients has revealed cannabis-dependent relationships with decreased bilateral ACC
volumes (Szeszko et al., 2007), left ACC volumes (Rapp et al., 2013), and increased
cortical thinning in the left ACC during the first five years of schizophrenia (Rais et al.,
2010). Thus, the evidence suggests that chronic cannabis use is related to reductions in
ACC gray matter, particularly in the left hemisphere. This may be because the left
hemisphere contains a higher CB1 receptor density (Glass et al., 1997). The ACC itself
is rich in CB1 receptors (Herkenham et al., 1990; Glass et al., 1997) and chronic
cannabis use leads to downregulation of CB1 receptors in the cingulate cortex
(Hirvonen et al., 2012). The eCB system modulates synaptic plasticity and, via CB1
receptors on glial cells, neuronal support (Pazos et al., 2005; Melis et al., 2014). Thus,
CB1 downregulation may lead to reduced dendritic branching or neuronal atrophy,
resulting in gray matter reductions (Lisdahl et al., 2014). Importantly, females may have
increased CB1 desensitization to THC in frontolimbic regions compared to males
(Crane et al., 2013). This may explain why females, but not males, in the current study,
demonstrated smaller left rACC volumes with increased cannabis exposure. Further,
reduced left rACC volumes were related to lower Discrimination Correct scores within
cannabis using females, but not males. This is consistent with other studies showing
volumetric differences in the PFC and amygdala associated with functional deficits in
female, but not male, cannabis users (Medina et al., 2009; McQueeny et al., 2011).
The link between exogenous cannabinoids, the ACC, and emotion processing has
been previously documented. Chronic cannabis users, compared to healthy controls,
have demonstrated altered ACC activation to masked emotional faces (Gruber et al.,
2009) and ACC hypoactivity in response to emotional scenes (Wesley et al., 2016).
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Acute THC administration enhanced functional connectivity between the rACC/mPFC
and amygdala during an emotion discrimination task in which participants were
instructed to decide which of two emotional (angry, fearful, or happy) faces matched a
third face (Gorka et al., 2015). On the other hand, acute CBD has been shown to
attenuate ACC activation and decrease connectivity between the ACC and amygdala in
response to fearful faces (Fusar-Poli et al., 2009; Fusar-Poli et al., 2010). The present
study supplements the fMRI literature by providing evidence for left rACC structural
abnormalities with chronic cannabis use in association with abnormal affective
processing. Notably, cannabis use predicted rostral, but not caudal ACC volumes.
Substantial past work suggests the rostral portion of the ACC supports emotional
processing, while the caudal region contributes more to cognitively demanding tasks by
influencing response selection, error detection, working memory, and monitoring
competition (Devinsky et al., 1995; Bush et al., 2000). Given the specialization of the
rACC, it is unsurprising that reduced left rACC volumes were associated with lower
Emotion Discrimination Correct scores in cannabis using females.
It is worth considering why Discrimination Correct was the only affective measure for
which a relationship was observed with left rACC. Perhaps the rACC serves a crucial
function in an aspect of the Emotion Discrimination task that is not present in the other
tasks. For example, it is possible that the rACC is critical in comparing two emotional
stimuli and making a decision regarding them. Previous research has identified the ACC
as important in emotion discrimination when one is presented with multiple faces
(Munro et al., 2007). Additionally, research suggests a role for the rACC in shifting
attention toward or away from emotional faces (Klumpp et al., 2012), which may be
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important if attending to multiple faces simultaneously. Another possibility is that the
Emotion Discrimination task was more difficult compared to the Emotion Recognition
and Emotional Acuity tasks, and thus the Discrimination task was more sensitive to
rACC abnormalities. In functional neuroimaging studies of cannabis users, aberrant
activation patterns often occur without differences in task performance (e.g., Cousijn et
al., 2014; Wesley et al., 2016), suggesting that cannabis users may be able to
compensate by adjusting which regions are recruited for a particular task. Thus,
perhaps female cannabis users in our sample were able to rely more heavily on other
brain areas besides the rACC while completing the Emotion Recognition and Emotional
Acuity tasks, but not the Emotion Discrimination task. However, a functional
neuroimaging study would be necessary in order to address this possibility.
Greater past year cannabis use also predicted larger right superior temporal
volumes, although this was not related to any affective processing measure in the
current sample. One past investigation revealed no superior temporal volume
alterations in cannabis users (DeLisi et al., 2006). However, others have reported
increased cortical thickness in the superior temporal gyrus in cannabis users compared
to non-users (Lopez-Larson et al., 2011; Epstein & Kumra, 2015). Moreover, adolescent
cannabis users have reduced cerebral blood flow in the left superior temporal gyrus
prior to abstinence (Jacobus et al., 2012), which may impact synaptic pruning
(Takahashi et al., 1999). Thus, structural aberrations in the superior temporal gyrus
could reflect insufficient synaptic pruning related to cannabis use. Alternatively,
increased right superior temporal volumes may indicate abnormal connectivity patterns
(Lisdahl et al., 2014), in which this region compensates for reduced efficiency in other
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regions more susceptible to exogenous cannabinoids, such as the PFC (Mackie et al.,
2005). Yet, it is not possible to conclude that this association between cannabis use and
increased superior temporal volumes reflects cortical damage or compensation without
evidence for behavioral deficits in our sample. Importantly, the association between
cannabis use and the superior temporal region did not survive correction for multiple
comparisons, indicating it may be a spurious finding. The superior temporal region is
involved in facial perception, auditory processing, and multisensory audiovisual
language processing (Ishai et al., 2005; Gazzaniga et al., 2014). Thus, future studies
should continue to investigate these functions in cannabis users in relation to superior
temporal areas.
The uncinate fasciculus is a tract connecting the anterior temporal lobe with frontal
regions, passing through the amygdala (Catani & Thiebaut de Schotten, 2012; Von Der
Heide et al., 2013). It supports episodic memory, language, and socio-emotional
processing (Von Der Heide et al., 2013). In contrast to our hypothesis, cannabis use
was significantly related to increased integrity, indicated by decreased mean diffusivity,
in the right uncinate fasciculus. Most studies have shown cannabis use to be associated
with decreased white matter integrity in various tracts, including in the uncinate
fasciculus (e.g., Jacobus et al., 2013a). Our own group found increased MD and
decreased FA in the uncinate fasciculus in a different sample of young adult cannabis
users (Shollenbarger et al., 2015). Importantly, mean past year use cannabis use
amongst users in that sample (548 joints) was more than double the amount in the
current study (228 joints). Therefore, it is possible that at lower doses, cannabis use
may actually improve white matter integrity. In fact, others have also noted increased
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white matter integrity in association with cannabis use, although in a different tract
(forceps minor) (Filbey et al., 2014). Cannabis has anti-inflammatory properties and has
been shown to specifically decrease inflammation in myelin, a major component of
white matter (for review, Burstein, 2015; Kozela et al., 2015). Reduced inflammation
leads to decreased tissue water and diffusion, which results in lower MD values
(Alexander et al., 2007). Additionally, cannabinoids possess neuroprotective and
antioxidant properties that may benefit white matter (Karl et al., 2012). Another
possibility is that the right uncinate fasciculus has abnormally strong connectivity in
order to compensate for observed structural abnormalities in the right temporal region,
which it connects with the PFC. Perhaps this initial compensation disappears with
heavier cannabis use. Age of cannabis use onset may also influence white matter
integrity and lead to differences in findings. Mean age of onset amongst cannabis users
in the present study as well as in the study by Filbey and colleagues (2014) was
relatively high at 17 and 18 years, respectively. Further, eCB genetics (i.e., FAAH
genotype) has been shown to moderate white matter integrity in cannabis users
(Shollenbarger et al., 2015). However, the relationship between greater cannabis use
and reduced right uncinate fasciculus MD did not survive correction for multiple
comparisons and as such, is of limited interpretability.
Cannabis use and gender interacted to predict forceps minor FA, such that females
tended to have increased FA with more use, while the opposite pattern was observed in
males. Previous studies demonstrated reduced white matter integrity in the forceps
minor (Jacobus et al., 2013; Shollenbarger et al., 2015) and anterior portions of the
corpus callosum (Arnone et al., 2008; Gruber et al., 2011; Gruber et al., 2014) in
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cannabis users compared to controls. Yet, increased forceps minor FA aligns with
Filbey and colleagues’ (2014) findings, although this was observed as a main effect in
their entire sample, which was predominantly male. The forceps minor is a fiber bundle
connecting the frontal lobes, including the rACC (Catani & Thiebaut de Schotten, 2012).
It is possible that females with greater cannabis use exhibited increased FA in the
forceps minor in order to compensate for reductions in rACC volume and function, while
this was not necessary for males, who did not exhibit rACC effects. As the rACC is high
in CB1 receptor density, perhaps the forceps minor is able to uniquely adjust to
exogenous cannabinoid influence (Filbey et al., 2014). Another possibility is that males
were more susceptible than females to the negative effects of cannabis on the forceps
minor, as frontal white matter takes longer to develop in males compared to females
(Simmonds et al., 2014). Further, factors such as THC: CBD ratios and genetics may
have differed between males and females in our sample, driving these differences in
FA. Additionally, this finding may be spurious as it did not survive correction for multiple
comparisons.
The present study has some important limitations. Firstly, in order to address
whether through use of PCA, more subtle behavioral relationships were missed,
supplementary regressions were run for cannabis use predicting individual PennCNP
variables. The only significant relationships were with Emotional Acuity Total Correct
and Emotional Acuity Happy Neutral Correct, which both loaded onto the Acuity Neutral
component, indicating that all variables demonstrating a significant relationship with
cannabis use were represented in components yielding significance. Second, due to the
cross-sectional, correlational nature of the study, it is not possible to determine the
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causal nature of the relationship between cannabis use and outcome variables. Further,
the cannabis exposure was lower than what is typically reported in previous publications
(average exposure 228 past year joints, with 39.4% using monthly or less frequently
and 24.2% using daily or more); therefore, these results may not generalize to young
adults with heavier use patterns. Similarly, length of cannabis abstinence was much
longer in our sample compared with most previous research (mean length of abstinence
57 days, minimum of 19 days). In most studies, users are abstinent for an average of 23 days, and research suggests there may be significant recovery with abstinence
(Lisdahl et al., 2014; D’Souza et al., 2016). Additionally, only one relationship (cannabis
predicting left rACC volumes) survived correction for multiple comparisons. As such, the
other significant associations found may be spurious and must be interpreted with
caution. We did not meet the sample size recommended (N=133) for 80% power at the
smallest effect size observed (f2=0.06); therefore, we only had adequate power
(recommended N= 74) for the effect size observed in the rACC (f2=0.11). Two brain
region measures, right lOFC volume and left uncinate fasciculus MD, exhibited trend
level relationships (p= 0.058 and p= 0.06, respectively) with past year cannabis use. It is
possible that with a larger sample size, significant effects may have been revealed.
Therefore, these findings should be replicated in a larger sample for increased power.
Finally, considering the study’s naturalistic design, there may other variables, including
age, genetics, THC:CBD ratios (for reviews, see Niesink & van Laar, 2013; Lorenzetti et
al., 2016), sex hormones, and physical fitness levels (Herting et al., 2012), moderating
the results. Future research should use longitudinal designs with larger sample sizes
and also measure these potential moderators.
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The current study provides evidence for a relationship between past year cannabis
use and reduced left rACC volumes in females, larger superior temporal volumes, and
decreased right uncinate fasciculus MD. Gender moderated the relationship between
cannabis use and forceps minor FA, with females demonstrating increased FA with
more use and males demonstrating the opposite relationship. Our most clinically
relevant and robust finding was greater past year cannabis use predicting smaller left
rACC volumes and within cannabis users, smaller left rACC volumes being associated
with lower scores on the Discrimination Correct component. Thus, chronic cannabis use
during adolescence and emerging adulthood, a time of continued neurodevelopment
(Casey et al., 2008), may negatively impact brain regions important for affective
processing. These neural abnormalities, in turn, are associated with difficulty
discriminating emotions, which may negatively influence mood and emotional well-being
(Phillips et al., 2003). Given the potential negative consequences of cannabis use as
evidenced by current and prior findings, more research on interventions for cannabis
use in youth is needed.
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Tables
Table 1
Participant Demographics
Aim 1: Affective/Behavioral (N=77)
Cannabis Users

Non-Users

(n=33)

(n=44)

% or M + SD

% or M + SD

(range)

(range)

Gender (% female)

36.4%

Race (% Caucasian)

Aim 2: Brain Structure (N=75)
Cannabis Users (n=32)

Non-Users (n=43)

% or M + SD (range)

% or M + SD (range)

54.5%

37.5%

53.5%

65.9%

69.7%

68.8%

67.4%

87.9%

88.6%

87.5%

88.4%

Age (years)

21.6±2.2 (18-26)

21.0±2.7 (16-25)

21.6 ± 2.2 (18-26)

21.0±2.7 (16-25)

WRAT-4 (raw score)

60.7±5.2 (41-69)

60.7 ± 5.3 (41-69)

62.0 ±3.8 (53-69)

Ethnicity (% NonHispanic)

Beck Depression
Inventory-II (BDI-II)

62.0 ±3.7 (5369)

5.7 ± 4.6 (0-18)*

2.6 ± 3.1 (0-10)*

5.8 ± 4.7 (0-18)*

2.6 ± 3.1 (0-10)*

17.5 ± 1.8 (13-21)

-

17.5 ± 1.8 (13-21)

-

Age of weekly
cannabis use onset
(years)
Lifetime cannabis use
(uses)
Past year cannabis use
(joints)
Length of cannabis
abstinence at Session
4 (days)
Past year alcohol use
(standard drinks)
Past year nicotine use
(cigarettes)
Session 4 cotinine
levels (0-6)
Session 5 cotinine
levels (0-6)
% Positive THC Urine
Toxicology Session 1
% Positive THC Urine

	
  

796.45 ± 1095.9
(25-6000)*
228.6 ± 306.2 (01394)*
57.2 ± 85.9 (19422)

3.4 ± 6.8 (0-25)*

6000)*

3.4 ± 6.8 (0-25)*

0.4 ± 1.1 (0-5)*

226.8 ± 310.9 (0-1394)*

0.4 ± 1.1 (0-5)*

-

58.1 ± 87.1 (19-422)

-

313.2 ±272.9 (0-

112.4 ± 178.8

897)*

(0-698.5)*

143.4 ±344.4 (0-

790.1 ± 1112.8 (25-

316.4 ± 276.7 (0-897)*

114.7 ± 180.2 (0698.5)*

0.5 ±1.9 (0-12)*

147.8 ± 348.9 (0-1165)*

0.5 ±1.9 (0-12)*

2.06 ± 1.7 (0-6)*

1.09 ± .6 (0-3)*

2.10 ± 1.7 (0-6)*

1.09 ± .6 (0-3)*

2.03 ± 1.6 (0-6)*

1.09 ± .7 (0-3)*

2.03 ± 1.6 (0-6)*

1.09 ± .7 (0-3)*

54.5%*

0%*

53.1%*

0%*

3%

0%

3.1%

0%

1165)*
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Toxicology Session 4
% Positive THC Urine
Toxicology Session 5

-

-

3.1%

Note. *Group differences: p< .05.
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Table 2. Emotion Recognition Principal Components Analysis Factor Loadings

Variable
Anger Correct
Fear Correct
Sad Correct
Happy Correct
Anger Correct Median
Response Time (ms)
Fear Correct Median
Response Time (ms)
Sad Correct Median
Response Time (ms)
Happy Correct Median
Response Time (ms)
Neutral Correct Median
Response Time (ms)

	
  

Recognition
Time
.121
-.262
-.001
.031
.660

Component Labels
Anger/Fear
Sad
Correct
Correct
.849
-.152
.627
.328
-.021
.935
-.018
-.001
.107
-.296

Happy
Correct
-.156
.323
.003
.950
-.033

.725

-.362

.014

-.261

.611

-.007

-.099

-.026

.765

.107

.380

-.009

.809

-.071

.069

.173

41

	
  

Table 3. Emotional Acuity Principal Components Analysis Factor Loadings

Variable
Total Correct
Very Happy Correct
Happy Neutral Correct
Neutral Correct
Sad Neutral Correct
Very Sad Correct
Correct Trials Median Response Time
(ms)
Correct Very Happy Trials Median
Response Time (ms)
Correct Happy Neutral Trials Median
Response Time (ms)
Correct Neutral Trials Median
Response Time (ms)
Correct Sad Neutral Trials Median
Response Time (ms)
Correct Very Sad Trials Median
Response Time (ms)

	
  

Component Labels
Acuity Time Acuity Neutral Acuity Intensity
-.096
.915
.380
-.074
-.093
.758
-.003
.879
-.129
-.154
.940
-.135
-.252
.746
-.025
.163
.076
.747
.947
-.199
.148
.806

.112

-.245

.744

-.388

.173

.887

-.293

.182

.860

-.155

.265

.603

.015

-.206
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Table 4.
Emotion Discrimination Principal Components Analysis Factor Loadings
Component Labels
Variable

Discrimination Time

Discrimination Correct

Total Correct

.094

.989

Happy Trials Correct

.114

.896

Sad Trials Correct

.041

.844

Correct Happy Trials Median Response
Time (ms)
Incorrect Happy Trials Median
Response Time (ms)
Correct Sad Trials Median Response
Time (ms)
Incorrect Sad Trials Median Response
Time (ms)
Total Correct Trials Median Response
Time (ms)

.921

-.013

.726

.375

.886

-.019

.778

.271

.974

-.017
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Table 5.
Significant Relationships Observed With p-values Before and After Correcting for
Multiple Comparisons
Relationship

p-value

Effect Size

FDR-corrected

(f2)

p-value

Cannabis àAcuity Neutral Component

0.047*

.06

0.470

CannabisàLeft rACC volume

0.002*

.11

0.014*

Cannabis*GenderàLeft rACC volume

0.036*

.07

0.252

Cannabisà Right superior temporal volume

0.027*

.06

0.189

Cannabisà Right uncinate MD

0.050*

.06

0.340

Cannabis*Genderàforceps minor FA

0.044*

.07

0.440

Note. *p< .05.
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Figures

B

A

C

Figure 1. All regions of interest that demonstrated a significant relationship with either
cannabis use or cannabis x gender prior to correction for multiple comparisons are
presented here on representative participants. A) Increased cannabis use and gender
significantly interacted to predict smaller left rACC volumes, such that only females
demonstrated this relationship. The left rACC is shown in red on this sagittal slice. B)
Greater cannabis use was associated with larger right superior temporal volumes,
highlighted in blue. C) This axial slice presents a ventral view of the brain. Increased
cannabis use was related to decreased right uncinate fasciculus (shown in blue) MD;
gender moderated the relationship between cannabis use and forceps minor (red) FA,
such that males had decreased FA with more cannabis use and females exhibited the
opposite pattern.
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Figure 2. After controlling for gender, past year alcohol use, and past year nicotine use,
a dose-dependent relationship was observed between greater past year cannabis use
and higher scores on the Acuity Neutral component.
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Figure 3. After controlling for gender, past year alcohol use, and past year nicotine use,
increased past year cannabis use was associated with larger right superior temporal
volumes. However, this relationship did not survive correction for multiple comparisons.
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Figure 4. Greater past year cannabis use significantly predicted smaller left rostral ACC
volumes. Gender significantly moderated this relationship, such that in females,
cannabis use was associated with reduced volumes, while in males, no significant
association between cannabis use and left rACC emerged. Covariates included gender,
past year alcohol use, and past year nicotine use. The main effect (cannabis use
predicting left rACC volumes) survived FDR corrections; however, the cannabis*gender
interaction was no longer significant after correcting for multiple comparisons.
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Figure 5. Greater past year cannabis use was significantly associated with reduced
mean diffusivity in the right uncinate fasciculus, indicating increased integrity.
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Figure 6. Cannabis*Gender significantly predicted fractional anisotropy (FA) in the
corpus callosum forceps minor, such that males exhibited reduced FA with increased
use; females had higher FA with increased cannabis use.
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Figure 7. Within the cannabis-using group, Pearson correlations revealed that smaller
left rACC volumes were associated with lower scores on the Discrimination Correct
component.
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